GlassScriptPhysician profile
Nicole Cohen
NPI 1427601897
$2,806.45
in general payments reported to CMS, 2019-2025
22 companies · $649 in 2025
The $649 reported for 2025 was more than what 90% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $699 · 2022: $224 · 2023: $794 · 2024: $441 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.53 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $530.06 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $323.49 | 2023-2025 | |
| Astellas Pharma US INC | $249.72 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $207.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Evofem Biosciences, INC. | $100.79 | 2024-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $87.96 | 2022-2025 | Slynd |
| Therapeuticsmd, INC. | $87.28 | 2021 | |
| Organon LLC | $76.01 | 2021-2024 | Nexplanon |
| Radius Health, INC. | $62.39 | 2021-2022 | |
| Shield Therapeutics INC | $60.59 | 2023 | Accrufer |
| Avion Pharmaceuticals | $55.02 | 2021-2022 | |
| Hologic Sales and Service, LLC | $54.96 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Millicent US INC | $48.31 | 2021-2025 | Intrarosa, Femring |
| Sumitomo Pharma America, INC. | $46.80 | 2023-2024 | Myfembree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $35.18 | 2025 | Zurzuvae |
| Pfizer INC. | $31.66 | 2023-2024 | |
| Ascend Therapeutics US, LLC | $19.10 | 2024 | |
| Amgen INC. | $18.30 | 2021 | |
| Lupin INC. | $16.43 | 2021 | |
| Lilly USA, LLC | $16.35 | 2024 | Mounjaro |
| Mission Pharmacal Company | $15.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.